Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Clinical trial NCT02983578 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02983578
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Colorectal Carcinoma Advanced Lung Non-Small Cell Carcinoma Lung Non-Small Cell Carcinoma Mismatch Repair Deficiency Refractory Colorectal Carcinoma Refractory Lung Carcinoma Refractory Pancreatic Carcinoma Stage II Pancreatic Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8

Start date: 2017-03-02
Primary completion: 2025-08-30
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.